WAIKOLOA, Hawaii — Aflibercept 8 mg improved injection intervals in previously treated eyes with wet age-related macular degeneration while improving vision in treatment-naive eyes, according to a speaker at Retina 2026.
Using the IRIS Registry, Theodore Leng, MD, MS, FACS, and colleagues explored real-world outcomes for Eylea HD (aflibercept 8 mg, Regeneron) by investigating patients who were either treatment naive (2,052 eyes) or who were switched to treatment with aflibercept 8 mg from Eylea (aflibercept 2 mg, Regeneron) (11,284 eyes). Primary outcomes included the last assigned injection